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Clinical Research Study

The Past, Present, and Future of Comparative
Effectiveness Research in the US Department of
Veterans Affairs
Joel Kupersmith, MD, Alexander K. Ommaya, ScD, MA
Office of Research and Development, US Department of Veterans Affairs, Washington, District of Columbia, USA.

ABSTRACT
A particular challenge for the healthcare provider and the patient is to choose among competing therapeutic
approaches for a particular condition. Often, the relative benefits and risks of potential therapies are not
uniformly available from the existing scientific information. Many have pointed to the need for more
comparative effectiveness research (CER) to aide in these decisions. The US Department of Veterans
Affairs (VA) has a long history of conducting CER. The success of the VA CER program has been
facilitated by several important aspects of scientific infrastructure related to (1) research question refinement, (2) study design, planning and coordination, (3) evidence synthesis, and (4) implementation research.
In publications that had VA coauthors in 2 major medical journals, 25% of the published studies were
classified as CER. The most frequent categories of study were pharmaceutical and behavioral interventions.
In the future, the CER enterprise will move toward increased input from clinicians in research topic choice
and enhanced consideration of other methodologies besides the randomized controlled trial.
© 2010 Published by Elsevier Inc. • The American Journal of Medicine (2010) 123, e3-e7
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A well-recognized challenge in the US healthcare system is
the consistent use of evidence in medical decision making.1,2 A particular challenge for the healthcare provider and
the patient is to choose among competing therapeutic approaches for a particular condition, e.g., choice of a particular drug for depression. Often, the relative benefits and
risks of potential therapies are not uniformly available from
the existing scientific information, a situation sometimes
referred to as the “inferential gap.”3,4
The availability of scientific information regarding effectiveness is more limited than information regarding efficacy, in part because studies designed for regulatory approval do not mirror “real-world” practice.5 However,
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efficacy data may also be limited, depending on the type of
intervention (drugs, medical devices, or surgical procedures), and the time that the intervention has been available
and its degree of use. In addition, treatments that have
demonstrated efficacy will not work for all patients. For
some they may be ineffective or harmful, e.g., patients with
comorbidities or different genetic compositions. For physicians and patients a key treatment question is often which of
the several alternative treatments should be considered. Efficacy trials, randomized controlled trials (RCTs), usually
exclude patients with comorbidities and therefore do not
provide direct evidence relevant to the most challenging
patient groups for healthcare providers to manage. RCTs are
also often designed with intermediate measures as endpoints, and thus do not provide the information most desired
by physicians, patients, and other medical decision makers.
Additionally, short follow-up times do not allow appreciation of survival or longer-term outcome measures. The 2007
report from the Medicare Payment Advisory Commission
concluded that there is not enough empirically based information for healthcare providers and patients to make informed treatment decisions.6 The commission also noted
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that variations in care are high when evidence is unclear.
Comparative research is most often available for cardiovascular and endocrine conditions and least available for neurologic and pulmonary conditions.7
There are several significant study design challenges in
conducting comparative effectiveness research (CER) in
general. In placebo-controlled trials a treatment is evaluated
in comparison to an inert treatment. In active-controlled
trials there is comparison of equivalence or noninferiority
with a prespecified amount of a comparator and a treatment
with known efficacy.8
The most robust design in an active-controlled study is
inclusion of a placebo group in a 3-arm design (when there
is equipoise for this arm and therefore ethical acceptability).
This design allows for direct demonstration of superiority in
reference to the placebo.9
For active-controlled trials, a new treatment should be
compared with standard treatment when there is sufficient
evidence such that it can serve as a reference treatment. The
reference treatment should have a well-established predictable effect at the dose and protocol to be tested. Intensity of
treatment and dose should be equipotent. The dose regimens
also should be comparable, and trial endpoints should not
favor a particular intervention.
It is important to guard against bias in comparative
studies, especially when methods other than RCTs are used.
Studies that rely only on administrative data may classify
cases inappropriately owing to missing information or may
lack information regarding relevant factors or exposures
(i.e., information or selection bias). Lack of data on potential confounders (i.e., factors that are associated with treatment and outcome) may also be an issue. Uses of methods
such as propensity scores and instrumental variables have
been described as approaches that can mimic randomization.10,11 Propensity scores are a quasi-experimental correction strategy in which a predicted probability of group
membership (control or experimental) is derived and may
also be used for matching, or as a covariate.12 Another
quasi-experimental method is use of instrumental variables.13 An instrumental variable is a variable that is correlated with the treatment and is related to the outcome only
through the association with treatment. Further descriptions
of these techniques are discussed by Concato and coworkers14 elsewhere in this supplement. Regardless of the analysis
approach used, the primary focus should be on reducing
sources of bias (e.g., multiple exposure bias) and adjusting for
confounding (e.g., adherence differences), rather than hoping
for a “magic bullet” provided by the methodological approach.15 At times, groups of studies with varying methodologies and approaches to patient follow-up may be appropriate.
The conduct of CER requires appropriate infrastructure
for successful completion of studies. The Federal Coordinating Council for CER research outlined infrastructure
needs for this research (Table 1). Depending on the question
and approach of the study various capabilities identified in
Table 1 will be required. The US Department of Veterans
Affairs (VA) has all of the aspects of the scientific infra-

Table 1 Comparative Effectiveness Research Scientific
Infrastructure
a. Administrative databases
b. EHRs and distributed data networks
c. Clinical research networks
d. Registries, surveillance databases, research-quality
observational datasets
e. Tools for dissemination and translation of research findings
f. Human and scientific capital

Table 2
●
●
●
●
●

Veterans Health Administration (FY2009)

Total enrollees in the VA healthcare system:
Total unique patients treated:
Number of VA medical centers:
Number of community-based outpatient clinics:
Number of VA Vet Centers*:

8.06M
5.74M
153
788
232

VA ⫽ US Department of Veterans Affairs.
*Vet Centers provide readjustment counseling, outreach, and referral
services.

structure outlined in Table 1. The VA is one of the largest
organized health systems and has the largest medical education and health professions training programs in the
United States.16 The VA’s medical facilities are affiliated
with 107 medical schools, 55 dental schools, and ⬎1,200
other schools. Roughly 90,000 health professionals are
trained in the VA each year. The number of patients treated
and medical facilities included in the Veterans Health System are indicated in Table 2. The VA electronic health
record is available at all sites of care.
CER with the greatest impact addresses questions that
focus on gaps in existing evidence, and, when completed,
provides timely information for medical decision making.17
The goal of the research is to facilitate the best use of
medical interventions or technologies, i.e., identifying
which types of patients would most benefit from particular
treatments. An Institute of Medicine (IOM) workshop held in
2001 highlighted the current deficiency and need for effectiveness research.18 Following this workshop, members of the
IOM Clinical Research Roundtable published recommendations regarding a definition of effectiveness research and mechanisms for research question formulation.19 More recently,
CER has received more attention, and a Patient-Centered Research Institute focusing on supporting CER was established as
part of Public Law No: 111-148. SEC 6301, 2010.
The VA CER research program is unique because it is
embedded within a national health system. The VA has the
resources and infrastructure (including electronic health
records, clinical research pharmacy, etc.) to fully support
and execute CER research, including large multicenter clinical trials. Additionally, roughly 70% of VA researchers are
also clinicians, exposing them to clinically relevant issues.
The VA Cooperative Studies Program (CSP) provides a
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RESULTS

Table 3 Distribution of US Department of Veterans Affairs
(VA) Comparative Effectiveness Research (CER) studies
published in 2 major medical journals over a 3-year period*

Type of comparison
Not CER
CER
Drug
Behavioral
Multiple
Procedure surgical or non surgical
Device
Grand Total
VA study topic (CER studies)
Cardiovascular disease
Other
Cancer
Diabetes mellitus
HIV
Mental health
Pain
Renal failure
Grand Total

Percent

n

75%
25%
12%
5%
3%
3%
2%

113
38
18
7
5
5
3
151

39%
13%
11%
11%
8%
8%
5%
5%

e5

15
5
4
4
3
3
2
2
38

HIV ⫽ human immunodeficiency virus.
*Published in The New England Journal of Medicine or Journal of the
American Medical Association with a VA coauthor between January 1,
2007 and December 31, 2009.

platform to collaboratively identify and refine research
questions, many of which are CER. To gather a better
understanding of VA CER, we reviewed articles that had
VA coauthors published in 2 leading medical journals to
determine the proportion of CER, the types of comparisons,
and the areas of focus.

METHODS
Thompson Reuters Science Citation Index Expanded was
searched to determine the number of publications in The
New England Journal of Medicine (NEJM) and the Journal
of the American Medical Association (JAMA) that included
VA coauthors. Publications that indicated “Veterans Affairs,” “Veterans Medical Center,” or “VA healthcare” in
the author address fields were selected. The search was
conducted on January 20, 2010 and included data from 2007
to 2009. Randomized trials, case-control studies, cohort
studies, and meta-analyses were included in the analyses.
Titles and abstracts of articles were reviewed by the coauthors,
and were identified as CER using the IOM definition. All
studies in which there was a comparison with an active treatment were selected as comparative effectiveness studies. The
comparator could involve a usual-care group if the usual care
was well defined. All publications identified in the search
included VA coauthors (n ⫽ 335). Letters, editorials, and corrections were excluded from the count (n ⫽ 184).

There were 151 articles, reviews, or proceedings papers identified with VA coauthors (Table 3). A total of 25% (n ⫽ 38)
were identified as CER studies. There was a wide variation in
the types of interventions investigated, with pharmaceuticals as
the most frequent category. Several studies involved varying
types of intervention (e.g., behavior/drug or device/procedure).
The distributions of the study topics are identified in Table 3.
The most frequent topic was cardiovascular disease. Examples
of the identified CER studies are listed in Table 4.20-26

DISCUSSION
The history of CER at the VA extends beyond 30 years.27,28
The VA has a dedicated scientific infrastructure for conducting CER that is embedded within the healthcare system.
The examples presented in Table 4 indicate the clinical
relevance of the CER conducted by VA investigators. In a
recent analysis of CER in 6 general medicine journals, the
supplementary online content provided a list of articles
published in NEJM and JAMA for a 16-month period.
Analysis of this list indicated that 26% (12 of 46) of all the
CER articles published in these 2 journals over the 16month period had VA coauthors. Taken together, the data
presented here, in addition to the analysis published by
Hochman and McCormick,7 indicate that the VA, despite its
relatively modest research budget, plays a significant role in
CER. Despite this effort, as Hochman and McCormick7
indicate, there is limited research devoted to assisting physicians in the effective use of therapies. Those unfamiliar
with the Veterans Health Administration and VA research
often assume that vast majority of research is focused solely
on deployment issues. However, as indicated in Table 3, and
because of the spectrum of health issues faced by veterans,
VA CER focuses on a variety of health issues relevant to the
general US population. The mechanism for assuring the
clinical relevance of these investigations is 2-fold. First,
roughly 70% of VA investigators are also clinicians; thus,
they are directly exposed to clinical needs. Second, the CSP,
which supported many of the studies identified in this analysis, begins by identifying questions with high clinical relevance submitted by clinical proponents.29 Involving these
stakeholders both at the beginning and in consultations with
the clinical system throughout the process appears to have
benefited the program in terms of the timeliness and clinical
relevance of research topics. Other important components
are the fixed infrastructure support (e.g., coordinating and
methodological centers, peer review) to help ensure the
quality of the research.30
The connection of the VA health system to VA research
allows for the identification and study of important questions that are relevant to the health system but might not
be raised by healthcare providers and manufacturers with
financial interests in the technology or procedure. An
example of a recent CER study is the Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, which showed that the majority of
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Table 4 Examples of Comparative Effectiveness Research Publications that Include US Department of Veterans Affairs (VA)
co-authors Published in The New England Journal of Medicine and Journal of the American Medical Association
Title

Comparison

Results

Cognitive Behavior Therapy for
Generalized Anxiety Disorder Among Older
Adults in Primary Care: A Randomized
Clinical Trial20
On-Pump versus Off-Pump Coronary-Artery
Bypass Surgery21

CBT vs. EUC

CBT resulted in greater improvement in worry severity,
depressive symptoms, and general mental health
compared with EUC

On Pump vs. off Pump

Bilateral Deep Brain Stimulation vs. Best
Medical Therapy for Patients: with
Advanced Parkinson Disease: A
Randomized Controlled Trial22

Bilateral deep brain stimulation
vs. best medical therapy

Risk of Adverse Outcomes Associated with
Concomitant Use of Clopidogrel and
Proton Pump Inhibitors Following Acute
Coronary Syndrome23
Glucose Control and Vascular
Complications in Veterans with Type 2
Diabetes24
Outcomes Following Endovascular vs.
Open Repair of Abdominal Aortic
Aneurysm: A Randomized Trial25
Optimal medical therapy with or without
PCI for stable coronary disease26

Clopidogrel with or without a
PPI

The off-pump group had worse composite outcomes
and poorer graft patency than patients in the onpump group
Deep brain stimulation was more effective in
improving time without dyskinesias, motor function,
and quality of life, but was associated with an
increased risk of serious adverse events compared
with best medical therapy
Increased risk of adverse outcomes was associated
with use of clopidogrel and PPI after hospital
discharge for ACS

Intensive vs. standard glucose
control
Endovascular vs. open repair of
abdominal aortic aneurysm
Optimal medical therapy vs.
percutaneous coronary
intervention

Intensive glucose control did not improve rates of
major cardiovascular events, death, or microvascular
complications
Perioperative mortality was reduced for endovascular
repair at 30 days, but there was no difference in
mortality at 2 yr
The PCI group and medical-therapy group were
comparable in the composite index of death,
myocardial infarction, and stroke; hospitalization
for ACS; or myocardial infarction

ACS ⫽ acute coronary syndromes; CBT ⫽ cognitive behavioral therapy; EUC ⫽ Enhanced usual care; PPI ⫽ proton pump inhibitor.

patients with optimal medical therapy had substantial improvements in health status for ⬎4 years.26 The COURAGE
findings are most applicable to patients with chronic stable
chest pain. The implication for clinical practice is that use of
percutaneous coronary intervention first should probably
not be adopted for patients with stable angina. In the month
following the publication of the article, US stent implants
declined by 13%, but by 2009 the number of implants
returned to previous levels.31 These data point to the challenges in translating research into healthcare practice and in
sustaining behavioral change. Evidence-based medical
guidelines (EBM), based on empirical research, have been
developed for many of the conditions identified in the IOM
report Crossing the Quality Chasm: A New Health System
for the 21st Century.32 Yet, health services researchers and
others have found that physicians and other healthcare providers frequently do not follow such guidelines.33-35 Some
of the obstacles to implementing EBM include the amount
and complexity of research; limitations on clinicians’ time;
policies that do not encourage use of EBM; organizational
barriers; lack of incentives to participate in educational
activities; experiences, beliefs, and attitudes of healthcare
providers that contradict EBM findings; local differences in
healthcare delivery; and patient experience, beliefs, and
attitudes that affect adherence.36,37 Variations in individual
patients may also limit implementation of EBM.38 The

Quality Enhancement Research Initiative (QUERI) is focused directly on this implementation problem in the VA.39
In the future, CER will be a much more prominent part
of the research enterprise and it, in turn, will have many
influences on both the research and clinical enterprises. The
interest and movement toward CER will influence how
research projects are identified and chosen, with more input
from clinicians and the healthcare system as in the VA CSP.
Also, recognition of the need for research efficiency will
move the field beyond the RCT to other methodologies
described above, though hopefully with great care.
Finally, CER will provide the information necessary to
better inform choices for patients, providers, and the healthcare system. The choices will not only rely on CER, as it is
currently considered, but on a complex of interacting and
coalescing research vehicles. CER will be one such vehicle
and personalized medicine, to address the issue of individual differences in response, another. Out of the synthesis
will come vast improvement in our approach to the health of
veterans and everyone else.
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